

CHARLES RIVER LABORATORIES INTERNATIONAL INC

Form 8-K

January 08, 2013

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 OR 15 (d) of the  
Securities Exchange Act of 1934

January 7, 2013  
Date of Report (Date of earliest event reported)

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.  
(Exact Name of Registrant as specified in its Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-15943  
(Commission File Number)

06-1397316  
(I.R.S. Employer  
Identification No.)

251 Ballardvale Street  
Wilmington, Massachusetts 01887  
(Address of Principal Executive Offices) (Zip Code)

781-222-6000  
(Registrant's Telephone Number, including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



ITEM 7.01.Regulation FD Disclosure

The following information (including Exhibit 99.1) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

On January 7, 2013, Charles River Laboratories International, Inc. (the "Registrant" or "Charles River") issued a press release which announced that it had closed the acquisition of Vital River, the premier commercial provider of research models and related services in China. In addition, the Registrant will be presenting at the J.P. Morgan 31st Annual Healthcare Conference in San Francisco, California, on Tuesday, January 8 th , at 10:00 a.m. PT (1:00 p.m. ET). Management of the Registrant intends to present an overview of the Registrant's strategic focus and business developments. Included in this overview will be information related to the effect of the Vital River acquisition on Charles River's 2013 guidance. In advance of the presentation, the Registrant has posted the accompanying slide presentation on the Investor Relations section of the Registrant's website. In addition, a copy of the slide presentation is incorporated herein by reference and filed as Exhibit 99.1 hereto.

The slide presentation, attached as an exhibit to this report, includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation are "forward-looking" rather than historic. The slide presentation also states that these and other risks relating to Charles River are set forth in the documents filed by Charles River with the Securities and Exchange Commission.

ITEM 9.01.Financial Statements and Exhibits

- (a) Not applicable.
- (b) Not applicable.
- (c) Exhibits.

99.1 J.P. Morgan 31st Annual Healthcare Conference Slide Presentation, dated January 8, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHARLES RIVER LABORATORIES  
INTERNATIONAL, INC.

Dated: January 8, 2013

By: /s/ Matthew L. Daniel  
Matthew L. Daniel, Corporate Vice President,  
Deputy General Counsel and Assistant Secretary

Exhibit Index

Exhibit No. Description

99.1 J.P. Morgan 31st Annual Healthcare Conference Slide Presentation, dated January 8, 2013

4

---